Eleclazine (GS-6615) is a novel and selective voltage-gated sodium channel inhibitor with antiarrhythmic properties that reduces peak sodium current (INaP) recorded from human induced pluripotent stem cell–derived cardiomyocytes.

在 Langendorff 灌流的离体兔心脏模型中，Eleclazine（1 μM，灌流 20 min）可在缺血再灌注损伤+心力衰竭背景下，缩小动作电位时程（APD）离散度、加快细胞内 Ca²⁺ 回收，从而抑制心律失常交替现象；在治疗性低温（33 °C，30 min）条件下，进一步改善 VF（心室颤动）的诱导率和严重程度[1]。